超越嵌合抗原受体T细胞：实体瘤的肿瘤浸润淋巴细胞疗法。 - Suppr

Suppr

超能文献

Beyond the CAR T Cells: TIL Therapy for Solid Tumors.

作者信息

Singh Rohit

机构信息

Immuno-oncology Branch, Division of Rare and Refractory Cancer, National Cancer Center, Goyang 10408, Korea.

出版信息

Immune Netw. 2024 Apr 18;24(2):e16. doi: 10.4110/in.2024.24.e16. eCollection 2024 Apr.

DOI:10.4110/in.2024.24.e16

PMID:38725673

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11076300/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1310/11076300/5ed94d91f6ba/in-24-e16-g001.jpg

相似文献

Beyond the CAR T Cells: TIL Therapy for Solid Tumors.超越嵌合抗原受体T细胞：实体瘤的肿瘤浸润淋巴细胞疗法。

Immune Netw. 2024 Apr 18;24(2):e16. doi: 10.4110/in.2024.24.e16. eCollection 2024 Apr.

TIL-Derived CAR T Cells Improve Immune Cell Infiltration and Survival in the Treatment of CD19-Humanized Mouse Colorectal Cancer.肿瘤浸润淋巴细胞来源的嵌合抗原受体T细胞在治疗CD19人源化小鼠结直肠癌中可改善免疫细胞浸润和生存期。

Cancers (Basel). 2023 Nov 24;15(23):5567. doi: 10.3390/cancers15235567.

Adoptive Immunotherapy beyond CAR T-Cells.过继性免疫疗法：超越嵌合抗原受体T细胞疗法

Cancers (Basel). 2021 Feb 11;13(4):743. doi: 10.3390/cancers13040743.

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.恶性肿瘤过继细胞免疫治疗的现状与展望。

Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231204198. doi: 10.1177/15330338231204198.

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.在 ALL 和 NHL 患者中比较自制 CD19 CAR-T 细胞。

J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000148.

Adoptive T cell therapy for solid tumors: current landscape and future challenges.过继性 T 细胞疗法治疗实体瘤：现状与未来挑战。

Front Immunol. 2024 Mar 14;15:1352805. doi: 10.3389/fimmu.2024.1352805. eCollection 2024.

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.HER2 CAR-T 细胞清除葡萄膜黑色素瘤和 IL2 转基因 NOD/SCID IL2 受体基因敲除小鼠中的 T 细胞治疗耐药性人类黑色素瘤。

Cancer Res. 2019 Mar 1;79(5):899-904. doi: 10.1158/0008-5472.CAN-18-3158. Epub 2019 Jan 8.

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.过继细胞疗法治疗实体瘤：当前的挑战与新兴治疗进展。

J Control Release. 2024 Apr;368:372-396. doi: 10.1016/j.jconrel.2024.02.033. Epub 2024 Mar 6.

Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?浸润肿瘤的淋巴细胞治疗实体瘤：需要双人探戈？

Front Immunol. 2022 Oct 28;13:1018962. doi: 10.3389/fimmu.2022.1018962. eCollection 2022.

Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.实体瘤患者肿瘤浸润淋巴细胞和血液淋巴细胞的功能特性：肿瘤细胞及其上清液对淋巴细胞增殖反应的影响。

J Immunol. 1986 Mar 1;136(5):1899-907.

引用本文的文献

Tumor microenvironment and immune-related myositis: addressing muscle wasting in cancer immunotherapy.肿瘤微环境与免疫相关肌炎：解决癌症免疫治疗中的肌肉萎缩问题

Front Immunol. 2025 May 2;16:1580108. doi: 10.3389/fimmu.2025.1580108. eCollection 2025.

Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?单核细胞是否是开发用于实体瘤的基于髓样细胞的疗法的更优选择？

J Exp Clin Cancer Res. 2025 Mar 15;44(1):98. doi: 10.1186/s13046-025-03359-x.

Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8 T and CAR-T cells.靶向 ROS 感应 Nrf2 增强肿瘤内 CD8 T 细胞和 CAR-T 细胞的抗肿瘤免疫。

Mol Ther. 2024 Nov 6;32(11):3879-3894. doi: 10.1016/j.ymthe.2024.08.019. Epub 2024 Aug 22.

本文引用的文献

Long-term outcomes following CAR T cell therapy: what we know so far.嵌合抗原受体 T 细胞疗法治疗后的长期结果：目前我们所了解的情况。

Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.一种采用肿瘤浸润淋巴细胞进行癌症过继性免疫治疗的新方法。

Science. 1986 Sep 19;233(4770):1318-21. doi: 10.1126/science.3489291.

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.肿瘤浸润淋巴细胞和白细胞介素-2在转移性黑色素瘤患者免疫治疗中的应用。初步报告。

N Engl J Med. 1988 Dec 22;319(25):1676-80. doi: 10.1056/NEJM198812223192527.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验